May 13, 2025 06:21AM
Dec 5, 2024 06:30AM
Dec 5, 2024 06:30AM
Sep 5, 2024 06:30AM
Jun 12, 2024 06:30AM
May 29, 2024 06:30AM
May 29, 2024 06:30AM Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
Nov 14, 2023 06:30AM
Nov 9, 2023 06:30AM
Sep 12, 2023 06:31AM
Sep 12, 2023 06:30AM
Aug 10, 2023 06:30AM
Jun 9, 2023 05:59PM
May 23, 2023 06:30AM Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
May 23, 2023 06:16AM
May 23, 2023 06:15AM
Mar 23, 2023 06:31AM
Mar 23, 2023 06:30AM
Jan 9, 2023 06:35AM
Jan 9, 2023 06:30AM
Nov 15, 2022 06:30AM Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress
Nov 3, 2022 09:15AM
Aug 11, 2022 06:30AM
Apr 13, 2022 09:15AM
Apr 11, 2022 09:18AM
Apr 11, 2022 05:33AM
Apr 10, 2022 12:05PM
Apr 10, 2022 12:05PM Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting
Mar 31, 2022 09:11AM
Mar 31, 2022 06:31AM
Mar 31, 2022 06:30AM
Jan 6, 2022 06:30AM
Apr 15, 2021 09:09AM
Apr 15, 2021 06:30AM
Apr 15, 2021 06:30AM Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
Apr 12, 2021 06:34AM
Apr 12, 2021 06:30AM
Apr 12, 2021 06:30AM
Apr 9, 2021 09:31AM
Mar 31, 2021 06:31AM
Mar 31, 2021 06:30AM
Mar 31, 2021 06:30AM Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid Tumors
Jan 7, 2021 06:31AM
Jan 7, 2021 06:30AM
Jan 7, 2021 06:30AM
Oct 20, 2020 06:35AM
Oct 20, 2020 06:30AM
Oct 20, 2020 06:30AM
Oct 20, 2020 06:30AM Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy
Aug 5, 2020 06:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All